Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
Abstract Background Edaravone has been widely used in amyotrophic lateral sclerosis (ALS) treatment, and a sublingual (SL) tablet has been developed to offer a more convenient alternative for injection. We present a cost-utility analysis to comprehensively evaluate the costs and health outcomes of o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-10-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-024-03381-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850179225589383168 |
|---|---|
| author | Chang Liu Yao Wu Fangxu Wang Shuang Sun Jiayin Wei Libo Tao |
| author_facet | Chang Liu Yao Wu Fangxu Wang Shuang Sun Jiayin Wei Libo Tao |
| author_sort | Chang Liu |
| collection | DOAJ |
| description | Abstract Background Edaravone has been widely used in amyotrophic lateral sclerosis (ALS) treatment, and a sublingual (SL) tablet has been developed to offer a more convenient alternative for injection. We present a cost-utility analysis to comprehensively evaluate the costs and health outcomes of oral and intravenous edaravone for the treatment of ALS in Chinese medical context. Methods Cost-utility analysis of SL tablets of edaravone versus intravenous edaravone at home was performed by constructing a 20-year Markov model of ALS stage 1–4 and death. The data were extracted from the literature with model assumptions. Typical sensitivity analysis and scenario analysis for administering SL tablets at home versus intravenous tablets at the hospital were performed. Results In the base case analysis, with SL tablets and intravenous injections both at home, the model estimated an additional cost of ¥12,670.04 and an additional 0.034 QALYs over 20 years (life time) of modeling analysis, and the ICER was ¥372,648.24 per QALY. However, in the scenario of intravenous administration at the hospital, SL tablet was demonstrated dominance to intravenous injection. Conclusions Using 3 times the GDP per capita of China in 2023 as the threshold, the SL tablet edaravone was not cost-effective in the context of home treatment for both formulationst, but was dominance to intravenous injection in hospital treatment. The results highlighted the importance of treatment context for health economic analysis. |
| format | Article |
| id | doaj-art-4004723ccda440c4a08e67a9d2245caf |
| institution | OA Journals |
| issn | 1750-1172 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj-art-4004723ccda440c4a08e67a9d2245caf2025-08-20T02:18:33ZengBMCOrphanet Journal of Rare Diseases1750-11722024-10-011911810.1186/s13023-024-03381-wCost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosisChang Liu0Yao Wu1Fangxu Wang2Shuang Sun3Jiayin Wei4Libo Tao5Center for Health Policy and Technology Evaluation, Peking University Health Science CenterCenter for Health Policy and Technology Evaluation, Peking University Health Science CenterCenter for Health Policy and Technology Evaluation, Peking University Health Science CenterCenter for Health Policy and Technology Evaluation, Peking University Health Science CenterCenter for Health Policy and Technology Evaluation, Peking University Health Science CenterCenter for Health Policy and Technology Evaluation, Peking University Health Science CenterAbstract Background Edaravone has been widely used in amyotrophic lateral sclerosis (ALS) treatment, and a sublingual (SL) tablet has been developed to offer a more convenient alternative for injection. We present a cost-utility analysis to comprehensively evaluate the costs and health outcomes of oral and intravenous edaravone for the treatment of ALS in Chinese medical context. Methods Cost-utility analysis of SL tablets of edaravone versus intravenous edaravone at home was performed by constructing a 20-year Markov model of ALS stage 1–4 and death. The data were extracted from the literature with model assumptions. Typical sensitivity analysis and scenario analysis for administering SL tablets at home versus intravenous tablets at the hospital were performed. Results In the base case analysis, with SL tablets and intravenous injections both at home, the model estimated an additional cost of ¥12,670.04 and an additional 0.034 QALYs over 20 years (life time) of modeling analysis, and the ICER was ¥372,648.24 per QALY. However, in the scenario of intravenous administration at the hospital, SL tablet was demonstrated dominance to intravenous injection. Conclusions Using 3 times the GDP per capita of China in 2023 as the threshold, the SL tablet edaravone was not cost-effective in the context of home treatment for both formulationst, but was dominance to intravenous injection in hospital treatment. The results highlighted the importance of treatment context for health economic analysis.https://doi.org/10.1186/s13023-024-03381-wEdaravoneSublingual tabletAmyotrophic lateral sclerosisCost-utility analysis |
| spellingShingle | Chang Liu Yao Wu Fangxu Wang Shuang Sun Jiayin Wei Libo Tao Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis Orphanet Journal of Rare Diseases Edaravone Sublingual tablet Amyotrophic lateral sclerosis Cost-utility analysis |
| title | Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis |
| title_full | Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis |
| title_fullStr | Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis |
| title_full_unstemmed | Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis |
| title_short | Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis |
| title_sort | cost utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis |
| topic | Edaravone Sublingual tablet Amyotrophic lateral sclerosis Cost-utility analysis |
| url | https://doi.org/10.1186/s13023-024-03381-w |
| work_keys_str_mv | AT changliu costutilityanalysisforsublingualversusintravenousedaravoneinthetreatmentofamyotrophiclateralsclerosis AT yaowu costutilityanalysisforsublingualversusintravenousedaravoneinthetreatmentofamyotrophiclateralsclerosis AT fangxuwang costutilityanalysisforsublingualversusintravenousedaravoneinthetreatmentofamyotrophiclateralsclerosis AT shuangsun costutilityanalysisforsublingualversusintravenousedaravoneinthetreatmentofamyotrophiclateralsclerosis AT jiayinwei costutilityanalysisforsublingualversusintravenousedaravoneinthetreatmentofamyotrophiclateralsclerosis AT libotao costutilityanalysisforsublingualversusintravenousedaravoneinthetreatmentofamyotrophiclateralsclerosis |